Lysine restricted diet for pyridoxine-dependent epilepsy: first evidence and future trials

Clara D M van Karnebeek1, Hans Hartmann, Sravan Jaggumantri

  • 1Division of Biochemical Diseases, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, Canada.

Insights

Dietary lysine restriction is safe and effective for children with pyridoxine-dependent epilepsy (PDE) caused by antiquitin deficiency. It reduces neurotoxic biomarkers and improves developmental outcomes and seizure control.

Area of Science:

  • Neuroscience
  • Metabolic Disorders
  • Pediatric Neurology

Background:

  • Pyridoxine-dependent epilepsy (PDE) is a rare genetic disorder caused by antiquitin (ATQ) deficiency.
  • Accumulation of neurotoxic metabolites like pipecolic acid and α-aminoadipic semialdehyde (AASA) contributes to neurological damage in PDE.
  • Current treatment involves pyridoxine therapy, but adjunctive strategies are needed.

Purpose of the Study:

  • To evaluate the efficacy and safety of dietary lysine restriction as an adjunct to pyridoxine therapy in children with ATQ deficiency-related PDE.
  • To assess the impact of lysine restriction on biochemical markers, seizure control, and developmental/cognitive outcomes.

Main Methods:

  • An observational study involving seven children with confirmed ATQ deficiency.
  • Implementation of dietary lysine restriction with regular nutritional monitoring.
  • Evaluation of biochemical markers (pipecolic acid, AASA, P6C) in body fluids.
  • Assessment of developmental/cognitive outcomes using standardized tests and parental reports.

Main Results:

  • Lysine restriction was well-tolerated with good compliance and no reported adverse events.
  • Significant reductions observed in plasma pipecolic acid (20-67%), urinary AASA (13-72%), plasma AASA (45%), and plasma P6C (42%).
  • Improvement in age-appropriate skills in 4/5 patients with pre-existing delays; seizure control maintained or improved in 6/7 children.
  • A single patient with diet interruption showed clinical deterioration and decreased CSF pipecolic acid (87.2%) and AASA (81.7%).

Conclusions:

  • Dietary lysine restriction is a safe and well-tolerated adjunctive therapy for PDE caused by ATQ deficiency.
  • It effectively reduces neurotoxic biomarkers and shows potential for improving developmental outcomes and seizure control.
  • Further high-level evidence is needed, supported by the establishment of an international PDE consortium and research infrastructure.
Abstract

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...